P76.60 FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation

Abstract

Conclusion: Osimertinib 80mg once daily presented good efficacy in pretreated EGFRm NSCLC patients with LM regardless of T790M status. Combined detection of cerebrospinal fluid and plasma testing could reveal more mechanisms of EGFR-tyrosine kinase inhibitors(TKIs) resistance.